Real-time Estimate
Cboe BZX
03:56:32 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
44.95
USD
|
+0.22%
|
|
+2.49%
|
+0.72%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
7,655
|
12,018
|
12,618
|
11,355
|
9,910
|
9,950
|
-
|
-
|
Enterprise Value (EV)
1 |
8,608
|
13,226
|
13,495
|
12,529
|
10,362
|
10,098
|
9,630
|
9,293
|
P/E ratio
|
-188
x
|
34.5
x
|
25.1
x
|
27.1
x
|
30.3
x
|
24.5
x
|
21.8
x
|
19.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.02
x
|
6.43
x
|
5.6
x
|
5.3
x
|
5.04
x
|
4.96
x
|
4.66
x
|
4.36
x
|
EV / Revenue
|
5.64
x
|
7.07
x
|
5.99
x
|
5.85
x
|
5.27
x
|
5.03
x
|
4.51
x
|
4.07
x
|
EV / EBITDA
|
15.6
x
|
17.7
x
|
15.3
x
|
15.9
x
|
15.7
x
|
14.1
x
|
12.4
x
|
11
x
|
EV / FCF
|
40.4
x
|
40.7
x
|
30
x
|
21.4
x
|
33.5
x
|
18.2
x
|
19.9
x
|
19.2
x
|
FCF Yield
|
2.47%
|
2.46%
|
3.33%
|
4.68%
|
2.99%
|
5.5%
|
5.02%
|
5.21%
|
Price to Book
|
3.08
x
|
4.31
x
|
4.08
x
|
3.28
x
|
2.71
x
|
2.55
x
|
2.29
x
|
2.09
x
|
Nbr of stocks (in thousands)
|
219,691
|
220,581
|
220,214
|
220,869
|
221,337
|
221,847
|
-
|
-
|
Reference price
2 |
34.85
|
54.48
|
57.30
|
51.41
|
44.77
|
44.85
|
44.85
|
44.85
|
Announcement Date
|
2/4/20
|
2/9/21
|
2/8/22
|
2/10/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
1,526
|
1,870
|
2,252
|
2,142
|
1,965
|
2,006
|
2,136
|
2,283
|
EBITDA
1 |
551.8
|
747.8
|
884.2
|
789.7
|
659
|
716
|
775.2
|
846.5
|
EBIT
1 |
421.8
|
626.8
|
755
|
656.3
|
528.6
|
562.2
|
613.4
|
671.3
|
Operating Margin
|
27.63%
|
33.51%
|
33.53%
|
30.65%
|
26.9%
|
28.03%
|
28.72%
|
29.4%
|
Earnings before Tax (EBT)
1 |
-77.78
|
439.5
|
625.8
|
512.6
|
429.8
|
500.5
|
565.7
|
630.2
|
Net income
1 |
-41.46
|
359.2
|
512.6
|
423.2
|
341.3
|
407.3
|
451.4
|
514.6
|
Net margin
|
-2.72%
|
19.2%
|
22.77%
|
19.76%
|
17.37%
|
20.31%
|
21.14%
|
22.54%
|
EPS
2 |
-0.1856
|
1.577
|
2.278
|
1.897
|
1.480
|
1.832
|
2.054
|
2.272
|
Free Cash Flow
1 |
212.9
|
325
|
449.1
|
586
|
309.7
|
555.7
|
483.5
|
483.7
|
FCF margin
|
13.95%
|
17.38%
|
19.95%
|
27.37%
|
15.76%
|
27.71%
|
22.64%
|
21.18%
|
FCF Conversion (EBITDA)
|
38.58%
|
43.46%
|
50.79%
|
74.21%
|
47%
|
77.61%
|
62.37%
|
57.15%
|
FCF Conversion (Net income)
|
-
|
90.49%
|
87.61%
|
138.47%
|
90.75%
|
136.44%
|
107.11%
|
93.99%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/4/20
|
2/9/21
|
2/8/22
|
2/10/23
|
2/6/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
582
|
628.4
|
516
|
500
|
498
|
485.4
|
494.9
|
475.9
|
509.2
|
458.8
|
495
|
506.4
|
537.9
|
489.3
|
525.4
|
EBITDA
1 |
231.6
|
266.4
|
178.7
|
175.9
|
168.6
|
157.6
|
168
|
158.2
|
175.3
|
153.3
|
171.2
|
180.1
|
196.7
|
165.7
|
180.4
|
EBIT
1 |
199.3
|
231.6
|
146.2
|
143.5
|
134.9
|
124.2
|
135.6
|
126.4
|
142.4
|
117.8
|
135.7
|
143.3
|
160.1
|
130.1
|
147.7
|
Operating Margin
|
34.24%
|
36.86%
|
28.33%
|
28.7%
|
27.09%
|
25.59%
|
27.4%
|
26.56%
|
27.97%
|
25.68%
|
27.41%
|
28.3%
|
29.76%
|
26.6%
|
28.11%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
95.72
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
129.2
|
155.3
|
96.66
|
82.39
|
88.84
|
85.04
|
80.79
|
77.82
|
97.66
|
80.67
|
99.68
|
103.7
|
116.4
|
105.4
|
124.8
|
Net margin
|
22.2%
|
24.72%
|
18.73%
|
16.48%
|
17.84%
|
17.52%
|
16.33%
|
16.35%
|
19.18%
|
17.58%
|
20.14%
|
20.47%
|
21.65%
|
21.55%
|
23.76%
|
EPS
2 |
0.5773
|
0.6907
|
0.4330
|
0.3711
|
0.4021
|
0.3814
|
0.3608
|
0.3505
|
0.4200
|
0.3600
|
0.4826
|
0.5076
|
0.5575
|
0.4394
|
0.5123
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/8/22
|
4/27/22
|
7/26/22
|
11/7/22
|
2/10/23
|
5/3/23
|
8/8/23
|
10/30/23
|
2/6/24
|
4/29/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
953
|
1,208
|
876
|
1,174
|
452
|
148
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
320
|
657
|
Leverage (Debt/EBITDA)
|
1.727
x
|
1.615
x
|
0.9912
x
|
1.486
x
|
0.6859
x
|
0.2066
x
|
-
|
-
|
Free Cash Flow
1 |
213
|
325
|
449
|
586
|
310
|
556
|
484
|
484
|
ROE (net income / shareholders' equity)
|
12.9%
|
18.9%
|
17.4%
|
12.9%
|
4.69%
|
11.9%
|
12.1%
|
12.1%
|
ROA (Net income/ Total Assets)
|
6.06%
|
9.02%
|
8.53%
|
6.81%
|
2.75%
|
6.72%
|
6.85%
|
6.7%
|
Assets
1 |
-684.1
|
3,982
|
6,008
|
6,217
|
12,403
|
6,062
|
6,590
|
7,678
|
Book Value Per Share
2 |
11.30
|
12.70
|
14.10
|
15.70
|
16.50
|
17.60
|
19.60
|
21.50
|
Cash Flow per Share
2 |
1.470
|
2.020
|
2.840
|
3.200
|
1.990
|
2.530
|
2.640
|
2.890
|
Capex
1 |
118
|
133
|
190
|
129
|
150
|
161
|
174
|
186
|
Capex / Sales
|
7.73%
|
7.1%
|
8.43%
|
6.03%
|
7.62%
|
8.03%
|
8.14%
|
8.14%
|
Announcement Date
|
2/4/20
|
2/9/21
|
2/8/22
|
2/10/23
|
2/6/24
|
-
|
-
|
-
|
Last Close Price
44.85
USD Average target price
50.14
USD Spread / Average Target +11.79% Consensus |
1st Jan change
|
Capi.
|
---|
| +0.72% | 9.95B | | +49.51% | 57.87B | | +41.65% | 40.25B | | -6.79% | 39.94B | | -5.96% | 28.54B | | +13.08% | 26.4B | | -19.80% | 19.33B | | +32.19% | 12.4B | | +0.48% | 12.23B | | +25.47% | 12.2B |
Other Biotechnology & Medical Research
|